Action Vela Minerals - VLA

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Dernier

0,145

Prix Achat

0,145

Prix Vente

0,18

Volume échangé

0,00 Fourchette du Jour 0,00

0,00 Plage de 52 semaines 0,00

Cap du marché

9,219M

Clôture Veille

0,145

Ouverture

Dernière Transaction

Dernière heure de transaction

Volume financier

VWAP

Volume moyen (3 m)

Actions en circulation

63 579 000

Rendement du Dividende

Ratio Cours sur Bénéfices

-21,54

Bénéfice par action (BPA)

-0,01

Chiffre d'affairess

Bénéfice net

-411k

Secteur

Miscellaneous Metal Ores,nec

Industrie

Miscellaneous Metal Ores,nec

Site Web

www.arbormetalscorp.com

Siège social

Vancouver, British Columbia, Can

Fondé

Vela Minerals Ltd est coté dans le secteur Miscellaneous Metal Ores de la TSX Venture Exchange avec le ticker VLA. Le dernier cours de clôture d'Vela Minerals était de $0,15. Au cours de la dernière année, les actions de Vela Minerals ont été négociées dans une fourchette de prix de $ 0,00 à $ 0,00.

Vela Minerals compte actuellement 63 579 000 actions en circulation. La capitalisation boursière d'Vela Minerals est de $9,22 million. Vela Minerals a un ratio cours/bénéfice (ratio PE) de -21.54.

Valneva and VBI Vaccines Announce European Partnership for Marketing and Distribution of PreHevbri®

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (Valneva) and VBI Vaccines Inc. (Nasdaq: VBIV) (VBI) today announced a partnership in select...

Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15

Approximately 6,000 participants 5 years of age and older will be enrolled in Lyme disease-endemic regions in Europe and the U.S. Pfizer Inc...

Valneva and Pfizer Enter into an Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate VLA15

Pfizer will invest €90.5 million in Valneva Planned Phase 3 study confirmed to initiate in Q3 2022 Valneva SE (Nasdaq: VALN; Euronext Paris:...

VALNEVA Reports Strong Business Performance in First Nine Months. Company Raises Financial Guidance for FY 2016

Lyon, France, Nov. 09, 2016 (GLOBE NEWSWIRE) -- Valneva Reports Strong Business Performance in First Nine Months Company Increases...

VALNEVA Announces Approval of an EB66(R)-based Prototype Influenza Vaccine in Japan

LYON, France, March 26, 2015 (GLOBE NEWSWIRE) -- The vaccine was developed by the Chemo-Sero Therapeutic Research Institute (Kaketsuken) in...

VALNEVA Reports Annual Results 2014: the company announces a significant improvement to its EBITDA and a strong reduction of ...

LYON, France, March 20, 2015 (GLOBE NEWSWIRE) -- Valneva Reports Annual Results 2014 The company announces a significant improvement to its...

VALNEVA announces signing of an exclusive license agreement on EB66(r) Cell Line for Human and Veterinary Vaccines in China

LYON, France, March 17, 2015 (GLOBE NEWSWIRE) -- Valneva announces signing of an exclusive license agreement on EB66® Cell Line for Human...

AMAG Pharmaceuticals Announces Appointment of Jim Sulat to Its Board of Directors and the Transition of Chairman Role to Gino...

WALTHAM, Mass., April 16, 2014 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

VLA - Frequently Asked Questions (FAQ)

What is the current Vela Minerals share price?

The current share price of Vela Minerals is $ 0,145

How many Vela Minerals shares are in issue?

Vela Minerals has 63 579 000 shares in issue

What is the market cap of Vela Minerals?

The market capitalisation of Vela Minerals is CAD 9,22M

What is the 1 year trading range for Vela Minerals share price?

Vela Minerals has traded in the range of $ 0,00 to $ 0,00 during the past year

What is the PE ratio of Vela Minerals?

The price to earnings ratio of Vela Minerals is -21,54

What is the reporting currency for Vela Minerals?

Vela Minerals reports financial results in CAD

What is the latest annual profit for Vela Minerals?

The latest annual profit of Vela Minerals is CAD -411k

What is the registered address of Vela Minerals?

The registered address for Vela Minerals is 2200 - 885 WEST GEORGIA STREET, VANCOUVER, BRITISH COLUMBIA, V6C 3G1

What is the Vela Minerals website address?

The website address for Vela Minerals is www.arbormetalscorp.com

Which industry sector does Vela Minerals operate in?

Vela Minerals operates in the MISCELLANEOUS METAL ORES,NEC sector

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
HCM.HHighcliff Metals Inc	$ 0,105 (950,00%)	3,5k
PERUChakana Copper Corp	$ 0,15 (900,00%)	21,35k
STUDStallion Uranium Corp	$ 0,13 (420,00%)	145k
JADEJade Leader Corp	$ 0,055 (175,00%)	213,5k
HCO.PHansco Capital Corp	$ 0,095 (171,43%)	1 000
MPTH.HMapath Capital Corp	$ 0,015 (-57,14%)	1 000
AQSAequus Pharmaceuticals Inc	$ 0,005 (-50,00%)	2k
CLMConsolidated Lithium Metals Inc	$ 0,005 (-50,00%)	281k
CPLCopper Lake Resources Ltd	$ 0,005 (-50,00%)	201k
NAVNAVCO Pharmaceuticals Inc	$ 0,005 (-50,00%)	7,79k
OMGOmai Gold Mines Corp	$ 0,35 (9,38%)	5,1M
PINNPinnacle Silver and Gold Corp	$ 0,04 (0,00%)	2,51M
QNCQuantum Emotion Corp	$ 0,68 (-2,86%)	2,15M
VPTVentripoint Diagnostics Ltd	$ 0,115 (-23,33%)	1,8M
AFMAlphamin Resources Corp	$ 0,74 (-3,90%)	1,73M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Vela Minerals Ltd (VLA)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

À propos de Vela Minerals Ltd

VLA Dernières nouvelles

Valneva and VBI Vaccines Announce European Partnership for Marketing and Distribution of PreHevbri®

Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15

Valneva and Pfizer Enter into an Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate VLA15

VALNEVA Reports Strong Business Performance in First Nine Months. Company Raises Financial Guidance for FY 2016

VALNEVA Announces Approval of an EB66(R)-based Prototype Influenza Vaccine in Japan

VALNEVA Reports Annual Results 2014: the company announces a significant improvement to its EBITDA and a strong reduction of ...

VALNEVA announces signing of an exclusive license agreement on EB66(r) Cell Line for Human and Veterinary Vaccines in China

AMAG Pharmaceuticals Announces Appointment of Jim Sulat to Its Board of Directors and the Transition of Chairman Role to Gino...

VLA - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Vela Minerals Ltd (VLA) Cours

Vela Minerals Ltd (VLA)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

À propos de Vela Minerals Ltd

VLA Dernières nouvelles

Valneva and VBI Vaccines Announce European Partnership for Marketing and Distribution of PreHevbri®

Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15

Valneva and Pfizer Enter into an Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate VLA15

VALNEVA Reports Strong Business Performance in First Nine Months. Company Raises Financial Guidance for FY 2016

VALNEVA Announces Approval of an EB66(R)-based Prototype Influenza Vaccine in Japan

VALNEVA Reports Annual Results 2014: the company announces a significant improvement to its EBITDA and a strong reduction of ...

VALNEVA announces signing of an exclusive license agreement on EB66(r) Cell Line for Human and Veterinary Vaccines in China

AMAG Pharmaceuticals Announces Appointment of Jim Sulat to Its Board of Directors and the Transition of Chairman Role to Gino...

VLA - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS